Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

Tackling challenges in the development of fixed-dose combinations

Anil Kane from Patheon spoke to Pharmaceutical Technology about the challenges in the development of FDCs and discussed how to integrate quality-by-design (QbD) in the manufacturing process of FDCs.
Apr 2, 2014

Anil Kane from Patheon spoke to Pharmaceutical Technology about the challenges in the development of FDCs and discussed how to integrate quality-by-design (QbD) in the manufacturing process of FDCs.

Current issues with nanomedicines

Raj Bawa, PhD, shares insight on the unresolved issues in nanomedicine development.
Mar 2, 2014

Despite the progress made in nanomedicine development, there are several issues that remain unresolved. Raj Bawa, PhD, provides insight.

Characterization of nanomedicines

A Q&A with Scott McNeil, PhD, director of the Nanotechnology Characterization Laboratory (NCL), on nanomedicine characterization.
Mar 2, 2014

Nanomedicines can offer promising benefits in the diagnosis and treatment of diseases but there are still concerns about the safety and quality of these therapeutics partly because of the lack of clear regulatory guidance. Scott McNeil, PhD, director of the Nanotechnology Characterization Laboratory (NCL), spoke with Pharmaceutical Technology about nanomedicine characterization.

Nanosimilars and follow-on nanomedicines

Stefan Muhlebach explains why non-biological complex drugs (NBCDs) cannot be assessed using the standard generic or biosimilar approaches.
Mar 2, 2014

With nanomedicines on the rise, a new class of non-biological complex drugs (NBCDs), which include nanosimilars, has emerged. As drug regulators are faced with the challenge of defining a framework to ensure the safe introduction of the follow-on nano-therapeutics, Stefan Muhlebach explains why NBCDs cannot be assessed using the standard generic or biosimilar approaches.

Pulmonary Drug Delivery—Particle Engineering for Inhaled Therapeutics

Industry experts discuss the various factors affecting drug delivery to the lungs and key considerations when developing inhalation formulations.
Feb 2, 2014

Experts discuss factors affecting drug delivery to the lungs and key considerations when developing inhalation formulations.

Can Pharma Defy Gravity at the Patent Cliff?

Formulation strategies for product lifecycle optimization.
Dec 11, 2013

Formulation strategies for product lifecycle optimization.

Can Pharma Defy Gravity at the Patent Cliff?

Formulation strategies for product lifecycle optimization.
Nov 2, 2013

Pharmaceutical companies are using formulation strategies as a lifecycle management tool to maximize product value and preserve their revenue streams.

New Single-Use Bioreactor Technology Emphasizes Ease-of-Use and Intelligent Process Control

An updated bioreactor based on rocking technology has more advanced controls but is easier for biopharmaceutical manufacturers to use.
Oct 23, 2013

An updated bioreactor based on rocking technology has more advanced controls but is easier for biopharmaceutical manufacturers to use.

New Technology Enables Integrated Chromatographic Separation and Mass Detection

Mass detection at the push of a button could change the way many laboratories carry out their chromatographic analysis.
Oct 23, 2013

Mass detection at the push of a button could change the way many laboratories carry out their chromatographic analysis.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here